Jeffrey Tong, PhD

Jeffrey Tong is a partner with Third Rock Ventures.  He has over 20 years in building and growing early stage biotechnology companies.  Prior to joining Third Rock, Jeff was executive chairman of the board of Delinia (acquired by Celgene), was president and CEO of Nora Therapeutics, and a founding member of the management team at Infinity Pharmaceuticals.  Over the course of his career, Jeff has raised significant capital from both equity markets and pharma partnerships, led teams from preclinical through phase 3 development, and developed integrated science/business strategies for building innovative biotechnology companies.  Earlier in his career, Jeff worked at McKinsey & Co. and was a founding researcher at the Harvard Bauer Center for Genomics Research. In addition to Septerna, he currently serves on the boards of Ambys Medicines, Asher Bio, Maze Therapeutics, and Nurix Therapeutics (NRIX).

Jeff received his educational training at the interface of molecular biology, organic chemistry and medicine and holds A.B. and M.M.S. degrees from Harvard College and Harvard Medical School, respectively, as well as A.M. and Ph.D. degrees from Harvard University.